medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 4

<< Back Next >>

Ann Hepatol 2011; 10 (4)

Citrus auraptene: A potential multifunctional therapeutic agent for nonalcoholic fatty liver disease

Sahebkar A

Language: English
References: 20
Page: 575-577
PDF size: 35.47 Kb.


ABSTRACT

Dear Editor

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease that encompasses a range of disorders from simple steatosis to cirrhosis and hepatocellular carcinoma. Although the pathophysiology of NAFLD has not been fully clarified, the “two-hit” hypothesis is currently regarded as the most widely accepted etiopathophysiologic model for this disorder.


REFERENCES

  1. Salt 2nd, WB. Nonalcoholic fatty liver disease (NAFLD): A comprehensive review. J Insur Med 2004; 36: 27-41.

  2. Epifano F, Genovese S, Curini M. Auraptene: Phytochemical and pharmacological properties. In: Matsumoto T (ed.). Phytochemistry research progressed. New York: Nova Science Publishers Inc.; 2008, p.145-62.

  3. Ogawa K, Kawasaki A, Yoshida T, Nesumi H, Nakano M, Ikoma Y, Yano M. Evaluation of auraptene content in citrus fruits and their products. J Agric Food Chem 2000; 48: 1763-9.

  4. Curini M, Cravotto G, Epifano F, Giannone G. Chemistry and biological activity of natural and synthetic prenyloxycoumarins. Curr Med Chem 2006; 13: 199-222.

  5. Genovese S, Epifano F. Auraptene: a natural biologically active compound with multiple targets. Curr Drug Targets 2011; 12: 381-6.

  6. Kohno H, Suzuki R, Curini M, Epifano F, Maltese F, Gonzales SP, Tanaka T. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. Int J Cancer 2006; 118: 2936-42.

  7. Prince M, Li Y, Childers A, Itoh K, Yamamoto M, Kleiner HE. Comparison of citrus coumarins on carcinogen-detoxifying enzymes in Nrf2 knockout mice. Toxicol Lett 2009; 185: 180-6.

  8. Murakami A, Nakamura Y, Tanaka T, Kawabata K, Takahashi D, Koshimizu K, Ohigashi H. Suppression by citrus auraptene of phorbol ester-and endotoxin-induced inflammatory responses: role of attenuation of leukocyte activation. Carcinogenesis 2000; 21: 1843-50.

  9. Takeda K, Utsunomiya H, Kakiuchi S, Okuno Y, Oda K, Inada K, Tsutsumi Y, et al. Citrus auraptene reduces Helicobacter pylori colonization of glandular stomach lesions in Mongolian gerbils. J oleo Sci 2007; 56: 253-60.

  10. Soltani F, Mosaffa F, Iranshahi M, Karimi G, Malekaneh M, Haghighi F, Behravan J. Auraptene from Ferula szowitsiana protects human peripheral lymphocytes against oxidative stress. Phytother Res 2010; 24: 85-9.

  11. Epifano F, Molinaro G, Genovese S, Ngomba RT, Nicoletti F, Curini M. Neuroprotective effect of prenyloxycoumarins from edible vegetables. Neurosci Lett 2008; 443: 57-60.

  12. Tanaka T, Sugiura H, Inaba R, Nishikawa A, Murakami A, Koshimizu K, Ohigashi H. Immunomodulatory action of citrus auraptene on macrophage functions and cytokine production of lymphocytes in female BALB/c mice. Carcinogenesis 1999; 20: 1471-6.

  13. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diab Obes Metab 2010; 12: 365-83.

  14. Kuroyanagi K, Kang MS, Goto T, Hirai S, Ohyama K, Kusudo T, Yu R, et al. Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2008; 366: 219-25.

  15. Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008; 14: 22-8.

  16. Takahashi N, Kang MS, Kuroyanagi K, Goto T, Hirai S, Ohyama K, et al. Auraptene, a citrus fruit compound, regulates gene expression as a PPARα agonist in HepG2 hepatocytes. BioFactors 2008; 33: 25-32.

  17. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 619-38.

  18. Tanaka T, De Azevedo MBM, Durán N, Alderete JB, Epifano F, Genovese S, Tanaka M, et al. Colorectal cancer chemoprevention by 2 β-cyclodextrin inclusion compounds of auraptene and 4'-geranyloxyferulic acid. Int J Cancer 2010; 126: 830-40.

  19. Murakami A, Nakamura Y, Tanaka T, Kawabata K, Takahashi D, Koshimizu K, Ohigashi H. Suppression by citrus auraptene of phorbol ester- and endotoxininduced inflammatory responses: Role of attenuation of leukocyte activation. Carcinogenesis 2000; 21: 1843-50.

  20. Nagao K, Yamano N, Shirouchi B, Inoue N, Murakami S, Sasaki T, Yanagita T. Effects of Citrus Auraptene (7-Geranyloxycoumarin) on hepatic lipid metabolism in vitro and in vivo. J Agric Food Chem 2010 [Epub ahead of print] DOI: 10.1021/jf1020329.




2020     |     www.medigraphic.com